Interleukin-2 and Oncolytic Virotherapy : A New Perspective in Cancer Therapy
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
By triggering immune responses in malignancies that have generally been linked to poor outcomes, immunotherapy has recently shown effectiveness. On the other hand, tumors provide an environment for cells that influence the body's immunity against cancer. Malignant cells also express large amounts of soluble or membrane-bound ligands and immunosuppressive receptors. In this regard, the combination of oncolytic viruses with pro-inflammatory or inflammatory cytokines, including IL-2, can be a potential therapy for some malignancies. Indeed, oncolytic viruses cause the death of cancerous cells and destroy the tumor microenvironment. They result in the local release of threat signals and antigens associated with tumors. As a result, it causes lymphocyte activity and the accumulation of antigenpresenting cells which causes them to accumulate in the tumor environment and release cytokines and chemokines. In this study, we reviewed the functions of IL-2 as a crucial type of inflammatory cytokine in triggering immune responses, as well as the effect of its release and increased expression following combination therapy with oncolytic viruses in the process of malignant progression, as an essential therapeutic approach that should be taken into consideration going forward.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Anti-cancer agents in medicinal chemistry - 23(2023), 18 vom: 27., Seite 2008-2026 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aghbash, Parisa Shiri [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer therapy |
|---|
| Anmerkungen: |
Date Revised 24.10.2023 published: Print Citation Status Publisher |
|---|
| doi: |
10.2174/1871520623666230727095154 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359977189 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359977189 | ||
| 003 | DE-627 | ||
| 005 | 20231226082024.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1871520623666230727095154 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1199.xml |
| 035 | |a (DE-627)NLM359977189 | ||
| 035 | |a (NLM)37497707 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aghbash, Parisa Shiri |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Interleukin-2 and Oncolytic Virotherapy |b A New Perspective in Cancer Therapy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 24.10.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a By triggering immune responses in malignancies that have generally been linked to poor outcomes, immunotherapy has recently shown effectiveness. On the other hand, tumors provide an environment for cells that influence the body's immunity against cancer. Malignant cells also express large amounts of soluble or membrane-bound ligands and immunosuppressive receptors. In this regard, the combination of oncolytic viruses with pro-inflammatory or inflammatory cytokines, including IL-2, can be a potential therapy for some malignancies. Indeed, oncolytic viruses cause the death of cancerous cells and destroy the tumor microenvironment. They result in the local release of threat signals and antigens associated with tumors. As a result, it causes lymphocyte activity and the accumulation of antigenpresenting cells which causes them to accumulate in the tumor environment and release cytokines and chemokines. In this study, we reviewed the functions of IL-2 as a crucial type of inflammatory cytokine in triggering immune responses, as well as the effect of its release and increased expression following combination therapy with oncolytic viruses in the process of malignant progression, as an essential therapeutic approach that should be taken into consideration going forward | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Oncolytic viruses | |
| 650 | 4 | |a cancer therapy | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a interleukin-2 | |
| 650 | 4 | |a neoplasms | |
| 650 | 4 | |a oncolytic virotherapy | |
| 700 | 1 | |a Rasizadeh, Reyhaneh |e verfasserin |4 aut | |
| 700 | 1 | |a Yari, Amir Hossein |e verfasserin |4 aut | |
| 700 | 1 | |a Lahouti, Shiva |e verfasserin |4 aut | |
| 700 | 1 | |a MotieGhader, Habib |e verfasserin |4 aut | |
| 700 | 1 | |a Nahand, Javid Sadri |e verfasserin |4 aut | |
| 700 | 1 | |a Entezari-Maleki, Taher |e verfasserin |4 aut | |
| 700 | 1 | |a Baghi, Hossein Bannazadeh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Anti-cancer agents in medicinal chemistry |d 2006 |g 23(2023), 18 vom: 27., Seite 2008-2026 |w (DE-627)NLM160693403 |x 1875-5992 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:18 |g day:27 |g pages:2008-2026 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1871520623666230727095154 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 18 |b 27 |h 2008-2026 | ||